Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts/Medco's Broad Reach Could Reshape Specialty Benefit Dynamics

Executive Summary

If it wins Federal Trade Commission approval, the proposed merger of Express Scripts Inc. and Medco Health Solutions Inc. would play out against a market driven in large part by high-priced specialty products and rampant genericization.

You may also be interested in...



Express Scripts-Medco Merger Closes With No Divestitures Needed

The FTC voted in a split 3-1 vote to close its investigation and allow Express Scripts’ $29.1 billion acquisition of rival PBM Medco to proceed.

Express Scripts-Medco Deal Fits Post-Health Reform Realities, But Was Hastened By Contract Losses

Express Scripts’ merger agreement with Medco to form a mega-pharmacy benefits manager may fit into the new realities of the post-health care reform world, but it was also likely hastened by contract losses at Medco.

What New Cancer Pathway Programs Mean For The Drug Industry

New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel